中國投融資(01226.HK)與浙江登雲小智科技訂立框架合作協議
格隆匯10月11日丨中國投融資(01226.HK)發佈公吿,於2021年10月11日,公司與浙江登雲小智科技發展有限公司訂立框架合作協議,內容有關公司投資合作方所推介及╱或與合作方共同投資非上市股權項目。
合作方是一家在中國成立的有限責任公司,合作方及其關聯公司所經營範圍包括但不限於健康養生旅遊渡假區、短視頻打賞電商、網上直播等業務。
董事會相信訂立框架合作協議能拓寬公司非上市股權投資業務,分散投資風險,籍着物色有盈利潛力項目,為股東帶來正面回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.